PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18448999-0 2008 Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer. Cisplatin 67-76 erb-b2 receptor tyrosine kinase 2 Homo sapiens 10-14 18448999-8 2008 CONCLUSIONS: Patients with HER2 FISH-positive LA-NSCLC had a poorer outcome even when treated with cisplatin-based chemoradiotherapy, despite the strong need for validation assessment of these observations. Cisplatin 99-108 erb-b2 receptor tyrosine kinase 2 Homo sapiens 27-31 18756958-0 2008 [Influence of human epidermal growth factor receptor-2 siRNA on chemosensitivity to cisplatin of human ovarian carcinoma cells: an in vitro experiment]. Cisplatin 84-93 erb-b2 receptor tyrosine kinase 2 Homo sapiens 20-54 18756958-1 2008 OBJECTIVE: To investigate the effects of RNA interference (RNAi) targeting human epidermal growth factor receptor 2 (HER-2) gene on the change of chemosensitivity to cisplatin of ovarian carcinoma cells. Cisplatin 166-175 erb-b2 receptor tyrosine kinase 2 Homo sapiens 117-122 18756958-12 2008 The proliferation rate of the SKOV3 cells transfected with HER-2 siRNA III and exposed to 1 microg/ml cisplatin was (58 +/- 5)%, significantly lower than those of the nonspecific siRNA III transfection group [(65 +/- 6)%] and the control group [(68 +/- 3)%, both P < 0.01]. Cisplatin 102-111 erb-b2 receptor tyrosine kinase 2 Homo sapiens 59-64 18756958-14 2008 The apoptosis rates at different time point of the HER-2 siRNA III + cisplatin group were all higher than those of the other 2 groups (all P < 0.01). Cisplatin 69-78 erb-b2 receptor tyrosine kinase 2 Homo sapiens 51-56 18756958-15 2008 The protein expression levels of the antiapoptotic proteins Bcl-2, survivin, and XIAP were of the HER-2 siRNA III + cisplatin group were significantly lower than those of the cisplatin group, and the protein expression level of the apoptotic protein Smac of the HER-2 siRNA III + cisplatin group significantly higher than that of the cisplatin group (all P < 0.05). Cisplatin 116-125 erb-b2 receptor tyrosine kinase 2 Homo sapiens 98-103 16681908-12 2006 After exposure to cisplatin for 24 hours, the survival rate of the HER-2 siRNA group was (58.4 +/- 0.8)%, significantly higher than those of the nonspecific siRNA group and control group, (68.0 +/- 0.6)% and (67.0 +/- 0.3)% respectively (both P < 0.001). Cisplatin 18-27 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-72 18756958-15 2008 The protein expression levels of the antiapoptotic proteins Bcl-2, survivin, and XIAP were of the HER-2 siRNA III + cisplatin group were significantly lower than those of the cisplatin group, and the protein expression level of the apoptotic protein Smac of the HER-2 siRNA III + cisplatin group significantly higher than that of the cisplatin group (all P < 0.05). Cisplatin 116-125 erb-b2 receptor tyrosine kinase 2 Homo sapiens 262-267 18756958-15 2008 The protein expression levels of the antiapoptotic proteins Bcl-2, survivin, and XIAP were of the HER-2 siRNA III + cisplatin group were significantly lower than those of the cisplatin group, and the protein expression level of the apoptotic protein Smac of the HER-2 siRNA III + cisplatin group significantly higher than that of the cisplatin group (all P < 0.05). Cisplatin 175-184 erb-b2 receptor tyrosine kinase 2 Homo sapiens 98-103 18756958-15 2008 The protein expression levels of the antiapoptotic proteins Bcl-2, survivin, and XIAP were of the HER-2 siRNA III + cisplatin group were significantly lower than those of the cisplatin group, and the protein expression level of the apoptotic protein Smac of the HER-2 siRNA III + cisplatin group significantly higher than that of the cisplatin group (all P < 0.05). Cisplatin 175-184 erb-b2 receptor tyrosine kinase 2 Homo sapiens 98-103 18756958-15 2008 The protein expression levels of the antiapoptotic proteins Bcl-2, survivin, and XIAP were of the HER-2 siRNA III + cisplatin group were significantly lower than those of the cisplatin group, and the protein expression level of the apoptotic protein Smac of the HER-2 siRNA III + cisplatin group significantly higher than that of the cisplatin group (all P < 0.05). Cisplatin 175-184 erb-b2 receptor tyrosine kinase 2 Homo sapiens 98-103 18756958-16 2008 CONCLUSIONS: HER-2 siRNA III induces cell apoptosis significantly and increases the sensitivity of the human ovarian carcinoma cells to cisplatin. Cisplatin 136-145 erb-b2 receptor tyrosine kinase 2 Homo sapiens 13-18 18756958-17 2008 The mechanism of induction of cell apoptosis by HER-2 siRNA III + cisplatin may be related to the downregulation of Bcl-2, survivin and XIAP protein and the up-regulation of Smac protein. Cisplatin 66-75 erb-b2 receptor tyrosine kinase 2 Homo sapiens 48-53 18337622-5 2007 Moreover, HER-2 expression was significantly associated with cisplatin sensitivity (p = 0.0089). Cisplatin 61-70 erb-b2 receptor tyrosine kinase 2 Homo sapiens 10-15 17885815-6 2008 Methotrexate (MTX), 5-florouracil (5-Fu), and cisplatin (CDDP) are commonly used for breast carcinoma treatment in clinics; however, patients with HER2/neu overexpression exhibit resistance to these anticancer drugs. Cisplatin 46-55 erb-b2 receptor tyrosine kinase 2 Homo sapiens 147-155 17885815-6 2008 Methotrexate (MTX), 5-florouracil (5-Fu), and cisplatin (CDDP) are commonly used for breast carcinoma treatment in clinics; however, patients with HER2/neu overexpression exhibit resistance to these anticancer drugs. Cisplatin 57-61 erb-b2 receptor tyrosine kinase 2 Homo sapiens 147-155 16549824-1 2006 PURPOSE: To evaluate the efficacy and safety of docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2 (HER2) -positive, locally advanced breast cancer (LABC). Cisplatin 59-68 erb-b2 receptor tyrosine kinase 2 Homo sapiens 160-164 16681908-13 2006 CONCLUSION: siRNA targeting HER-2 synthesized in vitro and transfected into human ovarian carcinoma cells effectively suppresses the HER-2 expression, induces cell apoptosis, and increases the sensitivity to cisplatin of the cells. Cisplatin 208-217 erb-b2 receptor tyrosine kinase 2 Homo sapiens 28-33 16638299-12 2006 CONCLUSION: Sequence specific siRNA-Her2/neu was capable of enhancing the chemosensitivity of Calu-3 cells to cisplatin. Cisplatin 110-119 erb-b2 receptor tyrosine kinase 2 Homo sapiens 30-44 15890569-0 2005 Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Cisplatin 233-242 erb-b2 receptor tyrosine kinase 2 Homo sapiens 55-60 16372489-0 2005 High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study. Cisplatin 33-42 erb-b2 receptor tyrosine kinase 2 Homo sapiens 77-81 16372489-14 2005 CONCLUSIONS: Combination chemotherapy with gemcitabine and cisplatin plus trastuzumab is well tolerated and active in patients with HER2 overexpressing MBC, even after prior exposure to anthracyclines and taxanes. Cisplatin 59-68 erb-b2 receptor tyrosine kinase 2 Homo sapiens 132-136 15585076-13 2004 The results of this study suggest that the docetaxel/cisplatin combination can be an effective and well-tolerated induction treatment of LABC, even in very large mostly HER2-nonoverexpressing tumors. Cisplatin 53-62 erb-b2 receptor tyrosine kinase 2 Homo sapiens 169-173 15703820-0 2005 Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. Cisplatin 124-133 erb-b2 receptor tyrosine kinase 2 Homo sapiens 20-29 12174876-6 2002 In contrast, erbB2-overexpressing cells showed statistically significant resistance to cisplatin, the P13K inhibitor LY294002 and the tyrosine kinase inhibitor emodin. Cisplatin 87-96 erb-b2 receptor tyrosine kinase 2 Homo sapiens 13-18 14998864-0 2004 Management of primary resistance to gemcitabine and cisplatin (G-C) chemotherapy in metastatic bladder cancer with HER2 over-expression. Cisplatin 52-61 erb-b2 receptor tyrosine kinase 2 Homo sapiens 115-119 15013588-1 2004 The purpose of this study was to evaluate the feasibility, efficacy, safety, and pharmacokinetics of trastuzumab plus cisplatin and gemcitabine in patients with Her2-overexpressing stages IIIB or IV non-small cell lung cancer (NSCLC) and to study the relationship between results from the two methods for determining levels of Her2 overexpression. Cisplatin 118-127 erb-b2 receptor tyrosine kinase 2 Homo sapiens 161-165 14512646-14 2003 Although some basic studies provide some important supports, studies including larger patient cohorts would still be required to prove the hypothesis that p53 and HER-2/neu-coexpressing tumors have a worse prognosis and are more resistant to a cisplatin-based multidrug regimen. Cisplatin 244-253 erb-b2 receptor tyrosine kinase 2 Homo sapiens 163-168 14512646-14 2003 Although some basic studies provide some important supports, studies including larger patient cohorts would still be required to prove the hypothesis that p53 and HER-2/neu-coexpressing tumors have a worse prognosis and are more resistant to a cisplatin-based multidrug regimen. Cisplatin 244-253 erb-b2 receptor tyrosine kinase 2 Homo sapiens 169-172 12174876-8 2002 Exposure of cells to geldanamycin, 17AAG, emodin, LY294002 and cisplatin led to depletion of erbB2 in the transfected cells. Cisplatin 63-72 erb-b2 receptor tyrosine kinase 2 Homo sapiens 93-98 12174876-9 2002 These data suggest that erbB2 status in ovarian cancr may contribute to chemosensitivity, in some cases leading to increased sensitivity (as with geldanamycin) but in other cases leading to resistance (as with cisplatin). Cisplatin 210-219 erb-b2 receptor tyrosine kinase 2 Homo sapiens 24-29 12452011-11 2002 CONCLUSIONS: The combination of HEL beta 1-PE38KDEL and cis-platin could promote the synergistic effect on apoptosis in the target cancer cells with high expression of erbB-2, 3, 4 which might be one of the mechanism of these two drugs. Cisplatin 56-66 erb-b2 receptor tyrosine kinase 2 Homo sapiens 168-174 12108894-9 2002 In addition, the results of the triple-drug combination of docetaxel, a platinum salt (cisplatin or carboplatin), and trastuzumab have resulted in impressive response rates and time to progression in a population of metastatic breast cancer patients with HER2/neu-positive tumors. Cisplatin 87-96 erb-b2 receptor tyrosine kinase 2 Homo sapiens 255-259 12108894-9 2002 In addition, the results of the triple-drug combination of docetaxel, a platinum salt (cisplatin or carboplatin), and trastuzumab have resulted in impressive response rates and time to progression in a population of metastatic breast cancer patients with HER2/neu-positive tumors. Cisplatin 87-96 erb-b2 receptor tyrosine kinase 2 Homo sapiens 260-263 12036454-3 2002 The combination of Trastuzumab and cisplatin is expected to be active against HER-2 / neu-expressing tumors. Cisplatin 35-44 erb-b2 receptor tyrosine kinase 2 Homo sapiens 78-83 12036454-3 2002 The combination of Trastuzumab and cisplatin is expected to be active against HER-2 / neu-expressing tumors. Cisplatin 35-44 erb-b2 receptor tyrosine kinase 2 Homo sapiens 86-89 12036454-10 2002 Both the expression of HER-2 / neu and the ADCC activity may be important determinants of the therapeutic benefit of the Trastuzumab/CDDP combination. Cisplatin 133-137 erb-b2 receptor tyrosine kinase 2 Homo sapiens 23-28 12036454-10 2002 Both the expression of HER-2 / neu and the ADCC activity may be important determinants of the therapeutic benefit of the Trastuzumab/CDDP combination. Cisplatin 133-137 erb-b2 receptor tyrosine kinase 2 Homo sapiens 31-34 11973639-8 2002 Profound growth inhibition was elicited by squalamine alone and by combined treatment with squalamine and cisplatin for both parental and HER-2-overexpressing ovarian tumor xenografts. Cisplatin 106-115 erb-b2 receptor tyrosine kinase 2 Homo sapiens 138-143 11973639-10 2002 Although HER-2-overexpressing tumors had more angiogenic and less apoptotic activity than parental cancers, growth of both tumor types was similarly suppressed by treatment with squalamine combined with cisplatin. Cisplatin 203-212 erb-b2 receptor tyrosine kinase 2 Homo sapiens 9-14 12070798-3 2002 A significant association between expression of c-erbB-2 mRNA und survival was obtained for the subgroup of patients who received a standard chemotherapy with carboplatin or cisplatin and cyclophosphamide (P = 0.0003). Cisplatin 174-183 erb-b2 receptor tyrosine kinase 2 Homo sapiens 48-56 11774202-7 2001 Emodin also sensitizes HER2/neu-overexpressing cancer cells to chemotherapeutic agents, including cisplatin, doxorubicin, etoposide, and paclitaxel. Cisplatin 98-107 erb-b2 receptor tyrosine kinase 2 Homo sapiens 23-27 11748447-4 2002 Introduction of HER-2 oncoprotein in vitro induces resistance to several anticancer drugs, including taxanes, cisplatin (CDDP) and 5-fluorouracil (5-FU) in breast cancer cells. Cisplatin 110-119 erb-b2 receptor tyrosine kinase 2 Homo sapiens 16-21 11748447-4 2002 Introduction of HER-2 oncoprotein in vitro induces resistance to several anticancer drugs, including taxanes, cisplatin (CDDP) and 5-fluorouracil (5-FU) in breast cancer cells. Cisplatin 121-125 erb-b2 receptor tyrosine kinase 2 Homo sapiens 16-21 10761709-2 2000 Overexpressions of epidermal growth factor receptor (EGFR) and HER-2/neu have been reported to affect the sensitivity of certain human cancer cells to cisplatin, presumably by modification of DNA repair activity through interference with NER. Cisplatin 151-160 erb-b2 receptor tyrosine kinase 2 Homo sapiens 63-72 11399867-0 2001 Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene. Cisplatin 25-34 erb-b2 receptor tyrosine kinase 2 Homo sapiens 84-93 11399867-0 2001 Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene. Cisplatin 25-34 erb-b2 receptor tyrosine kinase 2 Homo sapiens 95-103 11399867-5 2001 We investigated whether inhibition with antisense oligonucleotides against c-erbB-2 increased the sensitivity of MKN-7 and KATO-III cells to cisplatin. Cisplatin 141-150 erb-b2 receptor tyrosine kinase 2 Homo sapiens 75-83 11399867-6 2001 RESULTS: Antisense oligonucleotides for c-erbB-2 inhibited the expression of c-erbB-2 mRNA and protein and increased sensitivity to cisplatin, but not to other drugs, in MKN-7 and KATO-III cells. Cisplatin 132-141 erb-b2 receptor tyrosine kinase 2 Homo sapiens 40-48 11399867-8 2001 CONCLUSION: These findings indicate that c-erbB-2 expression in gastric cancer is one of the factors related to cisplatin sensitivity, and that anti-c-erbB-2 antisense oligonucleotides induced increased sensitivity to cisplatin. Cisplatin 112-121 erb-b2 receptor tyrosine kinase 2 Homo sapiens 41-49 11399867-8 2001 CONCLUSION: These findings indicate that c-erbB-2 expression in gastric cancer is one of the factors related to cisplatin sensitivity, and that anti-c-erbB-2 antisense oligonucleotides induced increased sensitivity to cisplatin. Cisplatin 112-121 erb-b2 receptor tyrosine kinase 2 Homo sapiens 149-157 11399867-8 2001 CONCLUSION: These findings indicate that c-erbB-2 expression in gastric cancer is one of the factors related to cisplatin sensitivity, and that anti-c-erbB-2 antisense oligonucleotides induced increased sensitivity to cisplatin. Cisplatin 218-227 erb-b2 receptor tyrosine kinase 2 Homo sapiens 149-157 10781891-4 2000 The aim of this study was to evaluate whether over-expression of the HER-2 receptor would modulate drug responsiveness to doxorubicin, cisplatin and taxol in ovarian cancer cells. Cisplatin 135-144 erb-b2 receptor tyrosine kinase 2 Homo sapiens 69-74 11899413-13 2001 Currently, several combinations of platinum compounds (either cisplatin or carboplatin) with docetaxel and trastuzumab are under clinical testing in patients with MBC who overexpress HER2/neu. Cisplatin 62-71 erb-b2 receptor tyrosine kinase 2 Homo sapiens 183-187 11899413-13 2001 Currently, several combinations of platinum compounds (either cisplatin or carboplatin) with docetaxel and trastuzumab are under clinical testing in patients with MBC who overexpress HER2/neu. Cisplatin 62-71 erb-b2 receptor tyrosine kinase 2 Homo sapiens 188-191 10697535-0 1999 Expression of activated c-erbB-2 oncogene induces sensitivity to cisplatin in human gallbladder adenocarcinoma cells. Cisplatin 65-74 erb-b2 receptor tyrosine kinase 2 Homo sapiens 24-32 10697535-1 1999 Overexpression of the c-erbB-2/HER-2/neu protooncogene which encodes for the tyrosine kinase receptor p185neu, has been observed frequently in cisplatin resistant human tumors, such as colorectal, breast, and non-small-cell lung cancers, and is known to induce resistance to cisplatin (CDDP) in vitro. Cisplatin 143-152 erb-b2 receptor tyrosine kinase 2 Homo sapiens 22-30 10697535-1 1999 Overexpression of the c-erbB-2/HER-2/neu protooncogene which encodes for the tyrosine kinase receptor p185neu, has been observed frequently in cisplatin resistant human tumors, such as colorectal, breast, and non-small-cell lung cancers, and is known to induce resistance to cisplatin (CDDP) in vitro. Cisplatin 143-152 erb-b2 receptor tyrosine kinase 2 Homo sapiens 31-40 10697535-1 1999 Overexpression of the c-erbB-2/HER-2/neu protooncogene which encodes for the tyrosine kinase receptor p185neu, has been observed frequently in cisplatin resistant human tumors, such as colorectal, breast, and non-small-cell lung cancers, and is known to induce resistance to cisplatin (CDDP) in vitro. Cisplatin 275-284 erb-b2 receptor tyrosine kinase 2 Homo sapiens 22-30 10697535-1 1999 Overexpression of the c-erbB-2/HER-2/neu protooncogene which encodes for the tyrosine kinase receptor p185neu, has been observed frequently in cisplatin resistant human tumors, such as colorectal, breast, and non-small-cell lung cancers, and is known to induce resistance to cisplatin (CDDP) in vitro. Cisplatin 275-284 erb-b2 receptor tyrosine kinase 2 Homo sapiens 31-40 10697535-1 1999 Overexpression of the c-erbB-2/HER-2/neu protooncogene which encodes for the tyrosine kinase receptor p185neu, has been observed frequently in cisplatin resistant human tumors, such as colorectal, breast, and non-small-cell lung cancers, and is known to induce resistance to cisplatin (CDDP) in vitro. Cisplatin 286-290 erb-b2 receptor tyrosine kinase 2 Homo sapiens 22-30 10697535-1 1999 Overexpression of the c-erbB-2/HER-2/neu protooncogene which encodes for the tyrosine kinase receptor p185neu, has been observed frequently in cisplatin resistant human tumors, such as colorectal, breast, and non-small-cell lung cancers, and is known to induce resistance to cisplatin (CDDP) in vitro. Cisplatin 286-290 erb-b2 receptor tyrosine kinase 2 Homo sapiens 31-40 10697535-2 1999 To confirm a direct relationship between erbB-2 expression and CDDP resistance, we examined the role of erbB-2 in the cellular sensitivity to cisplatin using erbB-2 transfected HAG-1 human gallbladder adenocarcinoma cell lines. Cisplatin 142-151 erb-b2 receptor tyrosine kinase 2 Homo sapiens 104-110 10697535-2 1999 To confirm a direct relationship between erbB-2 expression and CDDP resistance, we examined the role of erbB-2 in the cellular sensitivity to cisplatin using erbB-2 transfected HAG-1 human gallbladder adenocarcinoma cell lines. Cisplatin 142-151 erb-b2 receptor tyrosine kinase 2 Homo sapiens 104-110 10697535-3 1999 Three out of four cell lines, which stably expressed ErbB-2 protein (p185neu), did not show CDDP resistance but acquired sensitivity to cisplatin, compared to non-transfected cells. Cisplatin 136-145 erb-b2 receptor tyrosine kinase 2 Homo sapiens 53-59 10697535-5 1999 Although the mechanism still remains unclear, these results suggest that sensitivity to CDDP in erbB-2 expressed cells may vary, depending on the cell type. Cisplatin 88-92 erb-b2 receptor tyrosine kinase 2 Homo sapiens 96-102 10327070-1 1999 Previous studies have demonstrated a synergistic interaction between rhuMAb HER2 and the cytotoxic drug cisplatin in human breast and ovarian cancer cells. Cisplatin 104-113 erb-b2 receptor tyrosine kinase 2 Homo sapiens 76-80 10631474-0 1999 Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab. Cisplatin 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 27-30 10482199-1 1999 The anti-HER-2/neu antibody trastuzumab (Herceptin; Genentech, San Francisco, CA) interferes with DNA repair induced by cisplatin and, as a result, promotes cytotoxicity in HER-2/neu-overexpressing tumor target cells in a synergistic fashion. Cisplatin 120-129 erb-b2 receptor tyrosine kinase 2 Homo sapiens 9-14 10397267-5 1999 A significant association between expression of c-erbB-2 mRNA and survival was obtained for the subgroup of patients who received a standard chemotherapy with carboplatin or cisplatin and cyclophosphamide (P = 0.0003), whereas only a nonsignificant trend was observed for patients who did not receive a standard chemotherapy (P = 0.124). Cisplatin 174-183 erb-b2 receptor tyrosine kinase 2 Homo sapiens 48-56 10327070-3 1999 Synergistic interactions at clinically relevant drug concentrations were observed for rhuMAb HER2 in combination with cisplatin (CI=0.48, P=0.003), thiotepa (CI=0.67, P=0.0008), and etoposide (CI=0.54, P=0.0003). Cisplatin 118-127 erb-b2 receptor tyrosine kinase 2 Homo sapiens 93-97 9563896-4 1998 Clinical studies support an association between HER2 overexpression and resistance to alkylating agents (cisplatinum and cyclophosphamide). Cisplatin 105-116 erb-b2 receptor tyrosine kinase 2 Homo sapiens 48-52 9872333-6 1998 NSCLC cells which overexpress erbB-2 were more resistant to cisplatin-induced cytotoxicity in comparison to cells expressing low levels of erbB-2. Cisplatin 60-69 erb-b2 receptor tyrosine kinase 2 Homo sapiens 30-36 9845103-3 1998 The anti-erbB-2 sFv also sensitizes erbB-2 overexpressing cells to the cytotoxic effects of cisplatin. Cisplatin 92-101 erb-b2 receptor tyrosine kinase 2 Homo sapiens 9-15 9845103-3 1998 The anti-erbB-2 sFv also sensitizes erbB-2 overexpressing cells to the cytotoxic effects of cisplatin. Cisplatin 92-101 erb-b2 receptor tyrosine kinase 2 Homo sapiens 36-42 9811454-13 1998 As in studies of antibody-enhanced cisplatin cytotoxicity in vivo, treatment with rhuMAb HER-2 blocked the repair of cisplatin-damaged DNA only if the antibody was administered in close temporal proximity to transfection of the drug-exposed reporter DNA. Cisplatin 35-44 erb-b2 receptor tyrosine kinase 2 Homo sapiens 89-94 9811454-13 1998 As in studies of antibody-enhanced cisplatin cytotoxicity in vivo, treatment with rhuMAb HER-2 blocked the repair of cisplatin-damaged DNA only if the antibody was administered in close temporal proximity to transfection of the drug-exposed reporter DNA. Cisplatin 117-126 erb-b2 receptor tyrosine kinase 2 Homo sapiens 89-94 9811454-15 1998 Treatment with either cisplatin or doxorubicin led to an increase in unscheduled DNA synthesis that was reduced by combined therapy with antireceptor antibody specific to HER-2-overexpressing breast cancer cells. Cisplatin 22-31 erb-b2 receptor tyrosine kinase 2 Homo sapiens 171-176 9811454-16 1998 Using a direct measure of DNA repair, therapy of HER-2-overexpressing cells with rhuMAb HER-2 also blocked the removal of cisplatin-induced DNA adducts. Cisplatin 122-131 erb-b2 receptor tyrosine kinase 2 Homo sapiens 49-54 9811454-16 1998 Using a direct measure of DNA repair, therapy of HER-2-overexpressing cells with rhuMAb HER-2 also blocked the removal of cisplatin-induced DNA adducts. Cisplatin 122-131 erb-b2 receptor tyrosine kinase 2 Homo sapiens 88-93 9704716-0 1998 Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. Cisplatin 124-133 erb-b2 receptor tyrosine kinase 2 Homo sapiens 151-155 9704716-13 1998 CONCLUSION: The use of rhuMAb HER2 in combination with CDDP in patients with HER2/neu-overexpressing metastatic breast cancer results in objective clinical response rates higher than those reported previously for CDDP alone, or rhuMAb HER2 alone. Cisplatin 55-59 erb-b2 receptor tyrosine kinase 2 Homo sapiens 77-81 9704716-13 1998 CONCLUSION: The use of rhuMAb HER2 in combination with CDDP in patients with HER2/neu-overexpressing metastatic breast cancer results in objective clinical response rates higher than those reported previously for CDDP alone, or rhuMAb HER2 alone. Cisplatin 55-59 erb-b2 receptor tyrosine kinase 2 Homo sapiens 77-81 9704716-13 1998 CONCLUSION: The use of rhuMAb HER2 in combination with CDDP in patients with HER2/neu-overexpressing metastatic breast cancer results in objective clinical response rates higher than those reported previously for CDDP alone, or rhuMAb HER2 alone. Cisplatin 213-217 erb-b2 receptor tyrosine kinase 2 Homo sapiens 30-34 9662255-7 1998 c-erbB-2 expression/activity has been linked to sensitivity against CDDP. Cisplatin 68-72 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-8 7913407-2 1994 Agonistic antibodies against p185c-erbB-2 enhance the cytotoxic effect of the DNA alkylator, cisplatin, against c-erbB-2-overexpressing human carcinoma cells (Hancock et al., Cancer Res., 51:4575-4580, 1991). Cisplatin 93-102 erb-b2 receptor tyrosine kinase 2 Homo sapiens 33-41 9374379-0 1997 Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells. Cisplatin 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 91-96 9374379-6 1997 Both cisplatin-resistant lines expressed p185HER-2 and HER-2 mRNA at a higher concentration than the HTB-77wt cells. Cisplatin 5-14 erb-b2 receptor tyrosine kinase 2 Homo sapiens 45-50 9816272-4 1996 Therefore, we now demonstrate enhanced chemosensitivity to cis-diamminedichloroplatinum in erbB-2 overexpressing tumor cells and a model system of stable clones using an intracellular single chain antibody. Cisplatin 59-87 erb-b2 receptor tyrosine kinase 2 Homo sapiens 91-97 8637714-6 1996 Furthermore, the combination of emodin with cisplatin, doxorubicin or etoposide (VP16) synergistically inhibited the proliferation of HER-2/neu-overexpressing lung cancer cells, whereas low doses of emodin, cisplatin, doxorubicin, or VP16 alone had only minimal antiproliferative effects on these cells. Cisplatin 44-53 erb-b2 receptor tyrosine kinase 2 Homo sapiens 134-139 8637714-6 1996 Furthermore, the combination of emodin with cisplatin, doxorubicin or etoposide (VP16) synergistically inhibited the proliferation of HER-2/neu-overexpressing lung cancer cells, whereas low doses of emodin, cisplatin, doxorubicin, or VP16 alone had only minimal antiproliferative effects on these cells. Cisplatin 44-53 erb-b2 receptor tyrosine kinase 2 Homo sapiens 140-143 7896881-8 1995 ErbB-2-transformed MCF10-A cells responded to mitomycin, cisplatin, and 5-Fl-uracil, suggesting that signaling from activated ErbB-2 enhances the cells ability to respond to DNA damage. Cisplatin 57-66 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-6 7896881-8 1995 ErbB-2-transformed MCF10-A cells responded to mitomycin, cisplatin, and 5-Fl-uracil, suggesting that signaling from activated ErbB-2 enhances the cells ability to respond to DNA damage. Cisplatin 57-66 erb-b2 receptor tyrosine kinase 2 Homo sapiens 126-132 9150389-0 1997 Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway. Cisplatin 35-44 erb-b2 receptor tyrosine kinase 2 Homo sapiens 108-114 9150389-1 1997 We have examined the role of erbB-2 expression in the modulation of cellular toxicity to cisplatin. Cisplatin 89-98 erb-b2 receptor tyrosine kinase 2 Homo sapiens 29-35 9150389-4 1997 Using the host cell reactivation (HCR) of reporter gene expression from cisplatin-damaged plasmid and unscheduled DNA synthesis (UDS) following cisplatin treatment of cells, we have found that modulation of erbB-2 by TAb-250 was associated with inhibition of DNA repair. Cisplatin 72-81 erb-b2 receptor tyrosine kinase 2 Homo sapiens 207-213 9150389-4 1997 Using the host cell reactivation (HCR) of reporter gene expression from cisplatin-damaged plasmid and unscheduled DNA synthesis (UDS) following cisplatin treatment of cells, we have found that modulation of erbB-2 by TAb-250 was associated with inhibition of DNA repair. Cisplatin 144-153 erb-b2 receptor tyrosine kinase 2 Homo sapiens 207-213 9493954-4 1997 In general, tumor cells overexpressing erbB-2 are intrinsically resistant to DNA-damaging agents such as cisplatin. Cisplatin 105-114 erb-b2 receptor tyrosine kinase 2 Homo sapiens 39-45 8640763-4 1996 Compared to the low-p185(neu) expressing cell lines, we found that the high-p185(neu) expressing cell lines were more resistant to doxorubicin, etoposide, and cis-diamminedichloroplatinum(II) but more sensitive to AG825. Cisplatin 159-187 erb-b2 receptor tyrosine kinase 2 Homo sapiens 81-84 7911565-0 1994 Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Cisplatin 55-64 erb-b2 receptor tyrosine kinase 2 Homo sapiens 12-30 7911565-5 1994 In addition, antibody mediated an increased sensitivity to cisplatin in drug-resistant ovarian carcinoma cells containing multiple copies of HER-2/neu gene. Cisplatin 59-68 erb-b2 receptor tyrosine kinase 2 Homo sapiens 141-150 7911565-7 1994 Treatment with cisplatin led to a marked, dose-dependent increase in unscheduled DNA synthesis which was significantly reduced by combined treatment with antireceptor antibody in HER-2/neu-overexpressing cells. Cisplatin 15-24 erb-b2 receptor tyrosine kinase 2 Homo sapiens 179-184 7911565-7 1994 Treatment with cisplatin led to a marked, dose-dependent increase in unscheduled DNA synthesis which was significantly reduced by combined treatment with antireceptor antibody in HER-2/neu-overexpressing cells. Cisplatin 15-24 erb-b2 receptor tyrosine kinase 2 Homo sapiens 185-188 7911565-8 1994 Therapy with antibody to HER-2/neu receptor also led to a 35-40% reduction in repair of cisplatin-DNA adducts after cisplatin exposure and, as a result, promoted drug-induced killing in target cells. Cisplatin 88-97 erb-b2 receptor tyrosine kinase 2 Homo sapiens 25-43 7911565-8 1994 Therapy with antibody to HER-2/neu receptor also led to a 35-40% reduction in repair of cisplatin-DNA adducts after cisplatin exposure and, as a result, promoted drug-induced killing in target cells. Cisplatin 116-125 erb-b2 receptor tyrosine kinase 2 Homo sapiens 25-43 34729945-0 2021 HER2 targeting near-infrared photoimmunotherapy for a CDDP-resistant small-cell lung cancer. Cisplatin 54-58 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 1678683-0 1991 A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cisplatin 80-108 erb-b2 receptor tyrosine kinase 2 Homo sapiens 34-42 34729945-4 2021 RESULTS: We found that HER2 expression was upregulated on chemoresistant cell lines, especially cisplatin-resistance (SBC-3/CDDP). Cisplatin 96-105 erb-b2 receptor tyrosine kinase 2 Homo sapiens 23-27 34211587-1 2021 Background: Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. Cisplatin 38-47 erb-b2 receptor tyrosine kinase 2 Homo sapiens 170-174 34729945-4 2021 RESULTS: We found that HER2 expression was upregulated on chemoresistant cell lines, especially cisplatin-resistance (SBC-3/CDDP). Cisplatin 124-128 erb-b2 receptor tyrosine kinase 2 Homo sapiens 23-27 34729945-7 2021 CONCLUSION: In this study, we demonstrated that HER2 targeting NIR-PIT using trastuzumab is promising therapy for HER2-positive SCLC, and is more effective when HER2 expression is upregulated due to CDDP resistance, suggesting that the HER2 expression level positively corelated with the efficacy of NIR-PIT. Cisplatin 199-203 erb-b2 receptor tyrosine kinase 2 Homo sapiens 48-52 34729945-7 2021 CONCLUSION: In this study, we demonstrated that HER2 targeting NIR-PIT using trastuzumab is promising therapy for HER2-positive SCLC, and is more effective when HER2 expression is upregulated due to CDDP resistance, suggesting that the HER2 expression level positively corelated with the efficacy of NIR-PIT. Cisplatin 199-203 erb-b2 receptor tyrosine kinase 2 Homo sapiens 161-165 34729945-7 2021 CONCLUSION: In this study, we demonstrated that HER2 targeting NIR-PIT using trastuzumab is promising therapy for HER2-positive SCLC, and is more effective when HER2 expression is upregulated due to CDDP resistance, suggesting that the HER2 expression level positively corelated with the efficacy of NIR-PIT. Cisplatin 199-203 erb-b2 receptor tyrosine kinase 2 Homo sapiens 236-240 34386088-0 2021 Anthelminthic niclosamide inhibits tumor growth and invasion in cisplatin-resistant human epidermal growth factor receptor 2-positive breast cancer. Cisplatin 64-73 erb-b2 receptor tyrosine kinase 2 Homo sapiens 90-124 34386088-5 2021 The present study aimed to determine whether niclosamide can inhibit cell proliferation, invasion and epithelial-to-mesenchymal transition, as well as the stem-like phenotype in cisplatin-resistant HER2-positive breast cancer. Cisplatin 178-187 erb-b2 receptor tyrosine kinase 2 Homo sapiens 198-202 34386088-8 2021 The results from the present study demonstrated that niclosamide inhibited the resistance of HER2-positive breast cancer to cisplatin both in vitro and in vivo. Cisplatin 124-133 erb-b2 receptor tyrosine kinase 2 Homo sapiens 93-97 34386088-11 2021 Taken together, the results of the present study suggested that niclosamide combined with cisplatin may be considered as a novel treatment for chemoresistant HER2-positive breast cancer. Cisplatin 90-99 erb-b2 receptor tyrosine kinase 2 Homo sapiens 158-162 33538958-1 2021 PURPOSE: In the ToGA trial for HER2-positive advanced gastric cancer, cisplatin plus fluoropyrimidine was given for 6 cycles; trastuzumab was given until disease progression. Cisplatin 70-79 erb-b2 receptor tyrosine kinase 2 Homo sapiens 31-35 35070983-14 2021 Furthermore, quercetin combined with cisplatin downregulated the expression of EGFR, MYC, CCND1, and ERBB2 proteins and upregulated CASP8 expression in HeLa and SiHa cells. Cisplatin 37-46 erb-b2 receptor tyrosine kinase 2 Homo sapiens 101-106 33985511-0 2021 Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy. Cisplatin 40-49 erb-b2 receptor tyrosine kinase 2 Homo sapiens 8-12 33985511-5 2021 RESULTS: Human epidermal growth factor receptor 2 (Her2)-specific dimeric affibody (ZHer2) mediated cisplatin-loaded mesoporous polydopamine/MnO2/polydopamine nanoparticles (Pt@mPDA/MnO2/PDA-ZHer2 NPs) for MRI and enhanced chemo-radiotherapy of Her2-positive ovarian tumors is reported. Cisplatin 100-109 erb-b2 receptor tyrosine kinase 2 Homo sapiens 9-49 33985511-5 2021 RESULTS: Human epidermal growth factor receptor 2 (Her2)-specific dimeric affibody (ZHer2) mediated cisplatin-loaded mesoporous polydopamine/MnO2/polydopamine nanoparticles (Pt@mPDA/MnO2/PDA-ZHer2 NPs) for MRI and enhanced chemo-radiotherapy of Her2-positive ovarian tumors is reported. Cisplatin 100-109 erb-b2 receptor tyrosine kinase 2 Homo sapiens 51-55 33985511-5 2021 RESULTS: Human epidermal growth factor receptor 2 (Her2)-specific dimeric affibody (ZHer2) mediated cisplatin-loaded mesoporous polydopamine/MnO2/polydopamine nanoparticles (Pt@mPDA/MnO2/PDA-ZHer2 NPs) for MRI and enhanced chemo-radiotherapy of Her2-positive ovarian tumors is reported. Cisplatin 100-109 erb-b2 receptor tyrosine kinase 2 Homo sapiens 85-89 34268956-1 2021 PURPOSE: The purpose of this study was to compare the clinical efficacy and safety of S-1 + oxaliplatin (SOX) chemotherapy regimen combined with trastuzumab and irinotecan + cisplatin (IP) chemotherapy regimen combined with trastuzumab in treating human epidermal growth factor receptor 2 (HER-2)-positive advanced gastric cancer. Cisplatin 174-183 erb-b2 receptor tyrosine kinase 2 Homo sapiens 254-288 34268956-1 2021 PURPOSE: The purpose of this study was to compare the clinical efficacy and safety of S-1 + oxaliplatin (SOX) chemotherapy regimen combined with trastuzumab and irinotecan + cisplatin (IP) chemotherapy regimen combined with trastuzumab in treating human epidermal growth factor receptor 2 (HER-2)-positive advanced gastric cancer. Cisplatin 174-183 erb-b2 receptor tyrosine kinase 2 Homo sapiens 290-295 33042632-2 2020 The ToGA study showed that trastuzumab in combination with fluoropyrimidine plus cisplatin prolonged overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced GC (AGC). Cisplatin 81-90 erb-b2 receptor tyrosine kinase 2 Homo sapiens 146-180 33042632-2 2020 The ToGA study showed that trastuzumab in combination with fluoropyrimidine plus cisplatin prolonged overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced GC (AGC). Cisplatin 81-90 erb-b2 receptor tyrosine kinase 2 Homo sapiens 182-186 32494981-1 2020 BACKGROUND: We previously reported the HERBIS-4A phase II trial comparing S-1 plus cisplatin (SP) with capecitabine plus cisplatin (XP) in chemotherapy-naive patients with HER2-negative advanced gastric cancer (GC). Cisplatin 83-92 erb-b2 receptor tyrosine kinase 2 Homo sapiens 172-176 32117718-8 2020 Collectively, Cav-1 enhances the cisplatin-resistance of GC cells by activating the WNT signaling pathway and Met-HER2 crosstalk. Cisplatin 33-42 erb-b2 receptor tyrosine kinase 2 Homo sapiens 114-118 32943881-0 2020 Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report. Cisplatin 88-97 erb-b2 receptor tyrosine kinase 2 Homo sapiens 125-129 32269724-7 2020 Our study suggests that EGFR/ErbB2 activation is one of the driving pathways in developing cisplatin-resistance in ovarian cancer, and that sanguinarine has the potential to be developed as an effective therapy to overcome this therapeutic resistance. Cisplatin 91-100 erb-b2 receptor tyrosine kinase 2 Homo sapiens 29-34 31790894-18 2020 The combination of CDDP/PXD and TK or CuD inhibited ErbB2/ErbB3 dimerization. Cisplatin 19-23 erb-b2 receptor tyrosine kinase 2 Homo sapiens 52-57 30927036-1 2019 PURPOSE: The phase III ToGA trial established cisplatin, fluoropyrimidine and trastuzumab as the standard treatment in HER2-positive advanced gastric cancer (AGC). Cisplatin 46-55 erb-b2 receptor tyrosine kinase 2 Homo sapiens 119-123 31521263-2 2019 Herein, a synergetic targeted combination chemotherapy of doxorubicin (DOX) and cisplatin in breast cancer was realized by HER2 antibody-decorated nanoparticles assembled from aldehyde hyaluronic acid (AHA) and hydroxyethyl chitosan (HECS). Cisplatin 80-89 erb-b2 receptor tyrosine kinase 2 Homo sapiens 123-127 32156946-6 2019 Since HER2 was overexpressed in the primary tumor, he was treated with capecitabine, CDDP, and trastuzumab(XPT)therapy. Cisplatin 85-89 erb-b2 receptor tyrosine kinase 2 Homo sapiens 6-10 31102009-1 2019 BACKGROUND: Trastuzumab with cisplatin and fluoropyrimidines improves overall survival (OS) in patients with HER2-positive advanced gastric cancer (AGC). Cisplatin 29-38 erb-b2 receptor tyrosine kinase 2 Homo sapiens 109-113 31772741-5 2019 Given the HER2 overexpression, she was treated with trastuzumab, paclitaxel and cisplatin. Cisplatin 80-89 erb-b2 receptor tyrosine kinase 2 Homo sapiens 10-14 30856589-5 2019 Therefore, here, we propose a cisplatin-loaded, HER2 targeted poly(lactic-co-glycolic) nanoplatform, a system capable to escape the drug-efflux effect and to take advantage of the overexpressed HER2 receptors, using them as docks for targeted chemotherapy. Cisplatin 30-39 erb-b2 receptor tyrosine kinase 2 Homo sapiens 48-52 30856589-5 2019 Therefore, here, we propose a cisplatin-loaded, HER2 targeted poly(lactic-co-glycolic) nanoplatform, a system capable to escape the drug-efflux effect and to take advantage of the overexpressed HER2 receptors, using them as docks for targeted chemotherapy. Cisplatin 30-39 erb-b2 receptor tyrosine kinase 2 Homo sapiens 194-198 30809308-3 2019 Methods: An amphiphilic polymer coated magnetic iron oxide nanoparticle was conjugated with near infrared dye labeled HER2 affibody and chemotherapy drug cisplatin. Cisplatin 154-163 erb-b2 receptor tyrosine kinase 2 Homo sapiens 118-122 30088161-1 2019 BACKGROUND: Trastuzumab with cisplatin and fluoropyrimidine is the standard treatment in metastatic HER2-positive gastric or gastroesophageal (GE) junction adenocarcinoma; however, there is limited data on the efficacy of trastuzumab in combination with a three-drug regimen in this setting. Cisplatin 29-38 erb-b2 receptor tyrosine kinase 2 Homo sapiens 100-104 30711995-0 2019 Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202. Cisplatin 26-35 erb-b2 receptor tyrosine kinase 2 Homo sapiens 39-43 30711995-1 2019 BACKGROUND/AIM: Trastuzumab with S-1 plus cisplatin was proved to be effective for human epidermal growth factor receptor type 2 (HER2)-positive advanced gastric cancer with measurable lesions. Cisplatin 42-51 erb-b2 receptor tyrosine kinase 2 Homo sapiens 130-134 30711995-9 2019 CONCLUSION: Trastuzumab with S-1 plus cisplatin might be effective and tolerable for HER2-positive advanced gastric cancer without measurable lesions. Cisplatin 38-47 erb-b2 receptor tyrosine kinase 2 Homo sapiens 85-89 30799422-0 2019 A Rare Case of Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Gastroesophageal Junction with HER2/neu Overexpression and Distinct Orbital and Optic Nerve Toxicity after Intravenous Administration of Cisplatin. Cisplatin 203-212 erb-b2 receptor tyrosine kinase 2 Homo sapiens 26-29 30799422-6 2019 CASE REPORT: Herein we report a rare case of a 60-year-old male patient suffering from MANEC of the gastroesophageal junction with HER2/neu overexpression who developed severe orbital and ocular neurotoxicity (grade 3 according to CTCAE v4.03) after intravenous cisplatin. Cisplatin 262-271 erb-b2 receptor tyrosine kinase 2 Homo sapiens 131-139 28850174-23 2017 Testing all patients for HER-2 status may help to identify patients with HER-2-positive tumours, for whom, in the absence of contraindications, trastuzumab in combination with capecitabine or 5-FU in combination with cisplatin has been shown to be beneficial. Cisplatin 217-226 erb-b2 receptor tyrosine kinase 2 Homo sapiens 25-30 30145203-9 2018 Additional network analysis of significantly altered proteins revealed CDK2, CHEK1, and ERBB2 as central regulators mediating cisplatin resistance. Cisplatin 126-135 erb-b2 receptor tyrosine kinase 2 Homo sapiens 88-93 29290024-1 2018 BACKGROUND: Trastuzumab when combined with fluoropyrimidine and cisplatin was proven to improve survival in patients with human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) in the ToGA study. Cisplatin 64-73 erb-b2 receptor tyrosine kinase 2 Homo sapiens 128-162 29290024-1 2018 BACKGROUND: Trastuzumab when combined with fluoropyrimidine and cisplatin was proven to improve survival in patients with human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) in the ToGA study. Cisplatin 64-73 erb-b2 receptor tyrosine kinase 2 Homo sapiens 164-168 29090377-1 2018 BACKGROUND: Trastuzumab with fluoropyrimidine and cisplatin is the standard first-line treatment in patients with HER2-positive advanced gastro-esophageal adenocarcinoma. Cisplatin 50-59 erb-b2 receptor tyrosine kinase 2 Homo sapiens 114-118 28343375-12 2018 A positive crosstalk was shown between HER2 and MET, each of which increased resistance to lapatinib and/or cisplatin. Cisplatin 108-117 erb-b2 receptor tyrosine kinase 2 Homo sapiens 39-43 30692485-5 2018 Based on overexpression of the human epidermal growth factor receptor 2(HER2)protein in the primary tumor, we selected capecitabine plus cisplatin plus trastuzumab as the combination chemotherapy. Cisplatin 137-146 erb-b2 receptor tyrosine kinase 2 Homo sapiens 37-71 30692485-5 2018 Based on overexpression of the human epidermal growth factor receptor 2(HER2)protein in the primary tumor, we selected capecitabine plus cisplatin plus trastuzumab as the combination chemotherapy. Cisplatin 137-146 erb-b2 receptor tyrosine kinase 2 Homo sapiens 72-76 29451302-1 2018 According to the Trastuzumab for Gastric Cancer (ToGA) study, trastuzumab plus cisplatin and capecitabine/5-fluorouracil (5-FU) is standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced oesophagogastric cancer. Cisplatin 79-88 erb-b2 receptor tyrosine kinase 2 Homo sapiens 165-205 29451302-1 2018 According to the Trastuzumab for Gastric Cancer (ToGA) study, trastuzumab plus cisplatin and capecitabine/5-fluorouracil (5-FU) is standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced oesophagogastric cancer. Cisplatin 79-88 erb-b2 receptor tyrosine kinase 2 Homo sapiens 207-211 29174919-8 2018 Thus, the present case suggests that AFP and HER2 positive gastric cancer can be effectively treated with, capecitabine, cisplatin, and trastuzumab combination therapy. Cisplatin 121-130 erb-b2 receptor tyrosine kinase 2 Homo sapiens 45-49 29434871-5 2018 Phosphorylation of ErbB2 at Thr-677 was induced by CDDP and DOX, which in turn reduced tyrosine autophosphorylation of ErbB2 and ErbB3. Cisplatin 51-55 erb-b2 receptor tyrosine kinase 2 Homo sapiens 19-24 29434871-5 2018 Phosphorylation of ErbB2 at Thr-677 was induced by CDDP and DOX, which in turn reduced tyrosine autophosphorylation of ErbB2 and ErbB3. Cisplatin 51-55 erb-b2 receptor tyrosine kinase 2 Homo sapiens 119-124 26780095-3 2018 Here we present a case of complete tumor remission following third-line treatment with trastuzumab and gemcitabine in a patient with human epidermal growth factor receptor 2 (HER2)-positive UC after progression under cisplatin and vinflunine chemotherapies. Cisplatin 217-226 erb-b2 receptor tyrosine kinase 2 Homo sapiens 139-173 26780095-3 2018 Here we present a case of complete tumor remission following third-line treatment with trastuzumab and gemcitabine in a patient with human epidermal growth factor receptor 2 (HER2)-positive UC after progression under cisplatin and vinflunine chemotherapies. Cisplatin 217-226 erb-b2 receptor tyrosine kinase 2 Homo sapiens 175-179 28913549-0 2017 Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107. Cisplatin 48-57 erb-b2 receptor tyrosine kinase 2 Homo sapiens 90-124 28913549-1 2017 PURPOSE: S-1 plus cisplatin therapy is the recommended standard first-line regimen for human epidermal growth factor receptor 2 (HER-2)-negative advanced unresectable or recurrent gastric cancer (AGC) in the Japanese Gastric Cancer Treatment Guidelines. Cisplatin 18-27 erb-b2 receptor tyrosine kinase 2 Homo sapiens 87-127 28913549-1 2017 PURPOSE: S-1 plus cisplatin therapy is the recommended standard first-line regimen for human epidermal growth factor receptor 2 (HER-2)-negative advanced unresectable or recurrent gastric cancer (AGC) in the Japanese Gastric Cancer Treatment Guidelines. Cisplatin 18-27 erb-b2 receptor tyrosine kinase 2 Homo sapiens 129-134 28850174-23 2017 Testing all patients for HER-2 status may help to identify patients with HER-2-positive tumours, for whom, in the absence of contraindications, trastuzumab in combination with capecitabine or 5-FU in combination with cisplatin has been shown to be beneficial. Cisplatin 217-226 erb-b2 receptor tyrosine kinase 2 Homo sapiens 73-78 29108309-11 2017 Neoadjuvant chemotherapy by weekly paclitaxel and cisplatin combination was highly effective and tolerated in this study, especially in the triple negative and HER2 positive tumors. Cisplatin 50-59 erb-b2 receptor tyrosine kinase 2 Homo sapiens 160-164 28526406-3 2017 HER2-upregulated cisplatin- or etoposide-resistant SCLC cells were sensitive to trastuzumab-mediated ADCC. Cisplatin 17-26 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 28234911-0 2017 Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer. Cisplatin 17-26 erb-b2 receptor tyrosine kinase 2 Homo sapiens 89-93 28260018-3 2017 S-1 plus cisplatin is the standard treatment for HER2-negative advanced scirrhous gastric cancer in Japan. Cisplatin 9-18 erb-b2 receptor tyrosine kinase 2 Homo sapiens 49-53 28160563-8 2017 MiR-3622b-5p turned ERBB2-positive cancer cells more vulnerable to the apoptosis induced by cisplatin and 5-fluorouracil. Cisplatin 92-101 erb-b2 receptor tyrosine kinase 2 Homo sapiens 20-25 27284358-6 2016 The patient exhibited an elevated serum HER2 level, which prompted a reevaluation of the tissue by IHC, using an alternative antibody, and FISH; re-biopsy analyses confirmed the case as HER2-positive, and trastuzumab was subsequently added to the combination chemotherapy with capecitabine and cisplatin. Cisplatin 294-303 erb-b2 receptor tyrosine kinase 2 Homo sapiens 40-44 27760940-1 2016 We reported a case of human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer with multiple liver metastases that responded well to a combination of trastuzumab, capecitabine, and cisplatin(T-XP therapy)as first-line chemotherapy. Cisplatin 204-213 erb-b2 receptor tyrosine kinase 2 Homo sapiens 28-62 27760940-1 2016 We reported a case of human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer with multiple liver metastases that responded well to a combination of trastuzumab, capecitabine, and cisplatin(T-XP therapy)as first-line chemotherapy. Cisplatin 204-213 erb-b2 receptor tyrosine kinase 2 Homo sapiens 63-67 27002325-0 2016 A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer. Cisplatin 79-83 erb-b2 receptor tyrosine kinase 2 Homo sapiens 96-100 27002325-8 2016 CONCLUSIONS: Five-weekly S-1 and cisplatin combined with trastuzumab showed effective with favorable safety profile in patients with HER2-positive AGC. Cisplatin 33-42 erb-b2 receptor tyrosine kinase 2 Homo sapiens 133-137 26321717-3 2015 The cancer was HER2-positive; therefore, the patient was administered trastuzumab, capecitabine, and cisplatin combination therapy. Cisplatin 101-110 erb-b2 receptor tyrosine kinase 2 Homo sapiens 15-19 26489577-0 2015 [A Case of HER-2 Positive Advanced Gastric Cancer Responding to Capecitabine+Cisplatin+Trastuzumab Chemotherapy]. Cisplatin 77-86 erb-b2 receptor tyrosine kinase 2 Homo sapiens 11-16 26623038-1 2015 In the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction cancer, it has been reported that the combination of trastuzumab with capecitabine plus cisplatin, or with 5-fluorouracil (5-FU) plus cisplatin, significantly increased overall survival compared with chemotherapy alone (ToGA trial). Cisplatin 211-220 erb-b2 receptor tyrosine kinase 2 Homo sapiens 62-66 26623038-1 2015 In the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction cancer, it has been reported that the combination of trastuzumab with capecitabine plus cisplatin, or with 5-fluorouracil (5-FU) plus cisplatin, significantly increased overall survival compared with chemotherapy alone (ToGA trial). Cisplatin 257-266 erb-b2 receptor tyrosine kinase 2 Homo sapiens 62-66 26099969-13 2015 CONCLUSION: The combination of trastuzumab with S-1 and cisplatin demonstrated good activity, was generally well tolerated, and is a feasible treatment option in the first-line treatment of HER2-positive advanced gastric/GEJ cancers. Cisplatin 56-65 erb-b2 receptor tyrosine kinase 2 Homo sapiens 190-194 26846307-0 2016 Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. Cisplatin 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 64-68 26846307-3 2016 Herein, we found that HER2 upregulation was associated with cisplatin resistance. Cisplatin 60-69 erb-b2 receptor tyrosine kinase 2 Homo sapiens 22-26 26846307-4 2016 We observed that cisplatin-resistant gastric cancer cells underwent a morphological change similar to epithelial-mesenchymal transition (EMT) which is mediated by HER2 overexpression. Cisplatin 17-26 erb-b2 receptor tyrosine kinase 2 Homo sapiens 163-167 26846307-6 2016 More importantly, the IC50 and Resistance Index of resistant gastric cancer cells to cisplatin were also decreased by any of these treatments.We demonstrated that expression and amplification of HER2 positively correlated with expression of EMT-related transcription factor Snail in gastric cancer tissues. Cisplatin 85-94 erb-b2 receptor tyrosine kinase 2 Homo sapiens 195-199 26846307-8 2016 In conclusion, this study provides some clues of the association of cisplatin resistance with HER2 upregulation-induced EMT in gastric cancer cells. Cisplatin 68-77 erb-b2 receptor tyrosine kinase 2 Homo sapiens 94-98 26893657-0 2016 Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2. Cisplatin 43-52 erb-b2 receptor tyrosine kinase 2 Homo sapiens 109-114 26580554-6 2015 In contrast, sub-additive (antagonistic) interaction was observed for the combination of CDDP with VPA in MDA-MB-231 "triple-negative" (i.e. estrogen receptor negative, progesterone receptor negative, and HER-2 negative) human breast cancer cells, whereas combination of CDDP with SAHA in the same MDA-MB-231 cell line yielded additive interaction. Cisplatin 89-93 erb-b2 receptor tyrosine kinase 2 Homo sapiens 205-210 26571380-14 2015 Cisplatin, Abraxane and the MEK 1/2 inhibitor, Selumetinib were more active against mucin-IHCCA while, Gemcitabine, Gemcitabine-Cisplatin combination, the c-erbB2 blocking antibody and bestatin worked better against mixed-IHCCA. Cisplatin 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 155-162 26805121-5 2015 Chemotherapy, combined with molecular targeted therapy (S-1 plus cisplatin [CDDP] plus trastuzumab), was administered because of overexpression of the human epidermal growth factor receptor 2 (HER2) protein in the primary tumor as assessed by immunohistochemistry, the CEA levels decreased immediately after 2 cycles of the chemotherapy, and the liver metastases shrank markedly with no evidence of new lesions on abdominal CT. Cisplatin 65-74 erb-b2 receptor tyrosine kinase 2 Homo sapiens 193-197 26805121-5 2015 Chemotherapy, combined with molecular targeted therapy (S-1 plus cisplatin [CDDP] plus trastuzumab), was administered because of overexpression of the human epidermal growth factor receptor 2 (HER2) protein in the primary tumor as assessed by immunohistochemistry, the CEA levels decreased immediately after 2 cycles of the chemotherapy, and the liver metastases shrank markedly with no evidence of new lesions on abdominal CT. Cisplatin 76-80 erb-b2 receptor tyrosine kinase 2 Homo sapiens 157-191 26047983-8 2015 HER2 expression was higher in cell lines with acquired cisplatin resistance compared to the corresponding parental cell lines. Cisplatin 55-64 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 26321717-7 2015 In Japan, trastuzumab, capecitabine, and cisplatin combination therapy is currently recommended as the standard therapy for unresectable advanced/recurrent HER2-positive gastric cancer, and the findings of the present case suggest that it may also be useful as neoadjuvant chemotherapy. Cisplatin 41-50 erb-b2 receptor tyrosine kinase 2 Homo sapiens 156-160 25744576-1 2015 BACKGROUND: Trastuzumab with 5-fluorouracil (5-FU) and cisplatin offers prolonged survival in patients with HER2-overexpressing advanced gastric cancer (AGC) and advanced gastro-oesophageal junction cancer (AGOJ). Cisplatin 55-64 erb-b2 receptor tyrosine kinase 2 Homo sapiens 108-112 26313797-1 2015 A combination of trastuzumab and cisplatin or trastuzumab and capecitabine has been confirmed to be effective for treating adverse effects in with HER2-positive advanced gastric cancer (AGC) patients. Cisplatin 33-42 erb-b2 receptor tyrosine kinase 2 Homo sapiens 147-151 26054670-0 2015 Trastuzumab-cisplatin conjugates for targeted delivery of cisplatin to HER2-overexpressing cancer cells. Cisplatin 12-21 erb-b2 receptor tyrosine kinase 2 Homo sapiens 71-75 26054670-0 2015 Trastuzumab-cisplatin conjugates for targeted delivery of cisplatin to HER2-overexpressing cancer cells. Cisplatin 58-67 erb-b2 receptor tyrosine kinase 2 Homo sapiens 71-75 26054670-2 2015 Trastuzumab is a highly targeting protein to HER2 protein, and it is usually combined with paclitaxel or cisplatin for the treatment of HER2-overexpressing breast cancer. Cisplatin 105-114 erb-b2 receptor tyrosine kinase 2 Homo sapiens 136-140 25812508-0 2015 [A case of HER2-positive advanced gastric cancer successfully treated via capecitabine, cisplatin, and trastuzumab combination chemotherapy]. Cisplatin 88-97 erb-b2 receptor tyrosine kinase 2 Homo sapiens 11-15 25812508-1 2015 We report a case of human epidermal growth factor receptor 2 (HER2) -positive advanced gastric cancer effectively treated via capecitabine, cisplatin, and trastuzumab (XPT) chemotherapy followed by curative gastrectomy. Cisplatin 140-149 erb-b2 receptor tyrosine kinase 2 Homo sapiens 20-60 25812508-1 2015 We report a case of human epidermal growth factor receptor 2 (HER2) -positive advanced gastric cancer effectively treated via capecitabine, cisplatin, and trastuzumab (XPT) chemotherapy followed by curative gastrectomy. Cisplatin 140-149 erb-b2 receptor tyrosine kinase 2 Homo sapiens 62-66 26359224-6 2015 For HER2 positive cancer, standard treatments are combinations of fluoropyrimidine and cisplatin with trastuzumab. Cisplatin 87-96 erb-b2 receptor tyrosine kinase 2 Homo sapiens 4-8 25624920-0 2015 Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins. Cisplatin 102-111 erb-b2 receptor tyrosine kinase 2 Homo sapiens 41-45 25624920-1 2015 HER2 amplification occurs in ~20% of gastric cancer (GC) cases; however, in gastric and gastroesophageal junction cancer with HER2 gene amplification, trastuzumab in combination with cisplatin (DDP)-based chemotherapy has been reported to improve the oncological outcome. Cisplatin 183-192 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 25661103-1 2015 BACKGROUND: Trastuzumab has been approved for use in combination with fluoropyrimidine plus cisplatin for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC). Cisplatin 92-101 erb-b2 receptor tyrosine kinase 2 Homo sapiens 129-163 24218279-0 2014 Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer. Cisplatin 21-30 erb-b2 receptor tyrosine kinase 2 Homo sapiens 73-77 25143433-0 2015 Constitutively active ErbB2 regulates cisplatin-induced cell death in breast cancer cells via pro- and antiapoptotic mechanisms. Cisplatin 38-47 erb-b2 receptor tyrosine kinase 2 Homo sapiens 22-27 25099161-3 2014 A SILAC-based approach combined with TiO2-based phosphopeptide enrichment allowed the direct identification of ERK1/2, p90RSK, and ERBB2 as kinases whose phosphorylation is regulated by cisplatin. Cisplatin 186-195 erb-b2 receptor tyrosine kinase 2 Homo sapiens 131-136 25731506-1 2014 We report a case of human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer successfully treated with combination therapy of trastuzumab, capecitabine, and cisplatin, followed by a curative resection. Cisplatin 180-189 erb-b2 receptor tyrosine kinase 2 Homo sapiens 26-60 25731506-1 2014 We report a case of human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer successfully treated with combination therapy of trastuzumab, capecitabine, and cisplatin, followed by a curative resection. Cisplatin 180-189 erb-b2 receptor tyrosine kinase 2 Homo sapiens 61-65 25731518-0 2014 [A case of advanced HER2- positive gastric cancer with a partial response to molecular targeted chemotherapy (S-1+CDDP+Trastuzumab)]. Cisplatin 114-118 erb-b2 receptor tyrosine kinase 2 Homo sapiens 20-24 24218279-2 2014 Before the ToGA trial, HER2-positive GC in Japan was treated with S-1 plus cisplatin (SP). Cisplatin 75-84 erb-b2 receptor tyrosine kinase 2 Homo sapiens 23-27 23235178-6 2012 We become clear with HER2 strong positive in a pathology tissue and started capecitabine+cisplatin+trastuzumab therapy. Cisplatin 89-98 erb-b2 receptor tyrosine kinase 2 Homo sapiens 21-25 24782605-5 2014 The usefulness of HER2 targeted therapy in gastric cancer was demonstrated in the ToGA trial, where HER2-positive patients with advanced gastric and gastroesophageal junction adenocarcinoma were randomized to receive 5-FU/capecitabine and cisplatin, either alone or in combination with trastuzumab. Cisplatin 239-248 erb-b2 receptor tyrosine kinase 2 Homo sapiens 18-22 24048758-13 2014 In HER2-positive gastric cancer, the addition of the monoclononal anti-HER2 antibody trastuzumab to cisplatin and fluoropyrimidines has prolonged survival duration. Cisplatin 100-109 erb-b2 receptor tyrosine kinase 2 Homo sapiens 71-75 24803897-5 2014 Because immunohistochemical staining for HER2 was strong in both components, combination chemotherapy with capecitabine, cisplatin, and trastuzumab was initiated. Cisplatin 121-130 erb-b2 receptor tyrosine kinase 2 Homo sapiens 41-45 25374186-0 2014 Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer. Cisplatin 23-32 erb-b2 receptor tyrosine kinase 2 Homo sapiens 101-105 24394060-0 2013 [Two cases of human epidermal growth factor receptor 2-positive advanced gastric cancer successfully treated with S-1, cisplatin, and trastuzumab combination therapy followed by curative resection]. Cisplatin 119-128 erb-b2 receptor tyrosine kinase 2 Homo sapiens 14-54 24394060-1 2013 We report 2 cases of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer successfully treated with a combination therapy of S-1, cisplatin( CDDP), and trastuzumab followed by curative resection. Cisplatin 158-167 erb-b2 receptor tyrosine kinase 2 Homo sapiens 27-61 24394060-1 2013 We report 2 cases of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer successfully treated with a combination therapy of S-1, cisplatin( CDDP), and trastuzumab followed by curative resection. Cisplatin 158-167 erb-b2 receptor tyrosine kinase 2 Homo sapiens 63-67 24394060-1 2013 We report 2 cases of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer successfully treated with a combination therapy of S-1, cisplatin( CDDP), and trastuzumab followed by curative resection. Cisplatin 169-173 erb-b2 receptor tyrosine kinase 2 Homo sapiens 27-61 24394060-1 2013 We report 2 cases of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer successfully treated with a combination therapy of S-1, cisplatin( CDDP), and trastuzumab followed by curative resection. Cisplatin 169-173 erb-b2 receptor tyrosine kinase 2 Homo sapiens 63-67 24394076-0 2013 [A case of HER2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin, and trastuzumab as first-line chemotherapy]. Cisplatin 106-115 erb-b2 receptor tyrosine kinase 2 Homo sapiens 11-15 24394076-4 2013 Because overexpression of HER2 protein was observed in primary tumor immunostaining, combination therapy of capecitabine+CDDP+trastuzumab was administered as first-line chemotherapy. Cisplatin 121-125 erb-b2 receptor tyrosine kinase 2 Homo sapiens 26-30 24394077-0 2013 [A case of SPT therapy( S-1+CDDP+trastuzumab) was successful for HER2-positive gastric cancer accompanied by distant lymph node metastasis]. Cisplatin 28-32 erb-b2 receptor tyrosine kinase 2 Homo sapiens 65-69 24344005-0 2013 Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients. Cisplatin 13-22 erb-b2 receptor tyrosine kinase 2 Homo sapiens 74-79 24344005-1 2013 PURPOSE: To evaluate the activity and toxicity of the combination of capecitabine and cisplatin (CapCisp) in anthracycline- and taxane-pretreated HER-2 negative metastatic breast carcinoma (MBC) female patients. Cisplatin 86-95 erb-b2 receptor tyrosine kinase 2 Homo sapiens 146-151 24335926-0 2014 Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy. Cisplatin 34-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 49-53 24057416-9 2013 Trastuzumab in combination with cisplatin and a fluoropyrimidine is an effective regimen for patients with HER2-positive advanced gastric cancer, has acceptable tolerability and represents an important advance in the treatment of gastric cancer. Cisplatin 32-41 erb-b2 receptor tyrosine kinase 2 Homo sapiens 107-111 22458639-9 2013 Our findings indicated that the combination of lapatinib and cisplatin is one of the promising treatment strategies for esophageal carcinomas with EGFR and HER2 overexpression. Cisplatin 61-70 erb-b2 receptor tyrosine kinase 2 Homo sapiens 156-160 23863740-0 2013 [A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment]. Cisplatin 101-110 erb-b2 receptor tyrosine kinase 2 Homo sapiens 11-15 24649155-5 2013 The patient developed solitary liver metastasis one year later and was treated with trastuzumab plus capecitabine/cisplatin since results of the immunohistochemical analysis of the resected specimens demonstrated overexpression of the human epidermal growth factor receptor 2 (HER2). Cisplatin 114-123 erb-b2 receptor tyrosine kinase 2 Homo sapiens 241-275 24649155-5 2013 The patient developed solitary liver metastasis one year later and was treated with trastuzumab plus capecitabine/cisplatin since results of the immunohistochemical analysis of the resected specimens demonstrated overexpression of the human epidermal growth factor receptor 2 (HER2). Cisplatin 114-123 erb-b2 receptor tyrosine kinase 2 Homo sapiens 277-281 22467215-7 2012 Importantly, Bcl-2 silencing sensitizes these cells to chemotherapy (cisplatin) suggesting a potential new therapeutic approach for treating breast cancers with HER2(+)-status. Cisplatin 69-78 erb-b2 receptor tyrosine kinase 2 Homo sapiens 161-165 22546288-0 2012 SV40 T/t-common polypeptide enhances the sensitivity of HER2-overexpressing human cancer cells to anticancer drugs cisplatin and doxorubicin. Cisplatin 115-124 erb-b2 receptor tyrosine kinase 2 Homo sapiens 56-60 22546288-1 2012 HER2-overexpressing cancer cells are resistant to cisplatin (CDDP) and doxorubicin (DXR). Cisplatin 50-59 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 22546288-1 2012 HER2-overexpressing cancer cells are resistant to cisplatin (CDDP) and doxorubicin (DXR). Cisplatin 61-65 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 22546288-2 2012 Here we report that SV40 T/t-common polypeptide could specifically sensitize HER2-overexpressing cancer cells to CDDP and DXR and specifically enhance CDDP- or DXR-induced apoptosis in these cells. Cisplatin 113-117 erb-b2 receptor tyrosine kinase 2 Homo sapiens 77-81 22546288-2 2012 Here we report that SV40 T/t-common polypeptide could specifically sensitize HER2-overexpressing cancer cells to CDDP and DXR and specifically enhance CDDP- or DXR-induced apoptosis in these cells. Cisplatin 151-155 erb-b2 receptor tyrosine kinase 2 Homo sapiens 77-81 22788833-8 2012 CONCLUSIONS: The combination of low dose cisplatin and low dose UV-C synergistically exerted anti-cancer effect by down-regulating RTK, such as EGFR and HER2. Cisplatin 41-50 erb-b2 receptor tyrosine kinase 2 Homo sapiens 153-157 22349922-1 2012 PURPOSE: Preclinical data indicate that the combination of docetaxel, cisplatin and trastuzumab (TCH) may have the potential for clinically significant activity against breast cancers that overexpress the her2/neu gene (HER2). Cisplatin 70-79 erb-b2 receptor tyrosine kinase 2 Homo sapiens 205-213 22396490-7 2012 For example, low expression of the Xist gene correlated with cisplatin hypersensitivity in most tumors, and it also predicted long recurrence-free survival of HER2-negative, stage III breast cancer patients treated with intensive platinum-based chemotherapy. Cisplatin 61-70 erb-b2 receptor tyrosine kinase 2 Homo sapiens 159-163 22349922-1 2012 PURPOSE: Preclinical data indicate that the combination of docetaxel, cisplatin and trastuzumab (TCH) may have the potential for clinically significant activity against breast cancers that overexpress the her2/neu gene (HER2). Cisplatin 70-79 erb-b2 receptor tyrosine kinase 2 Homo sapiens 220-224 22116464-0 2012 Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer. Cisplatin 45-54 erb-b2 receptor tyrosine kinase 2 Homo sapiens 122-126 22222640-1 2012 Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the European Medicines Agency for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive (immunohistochemistry 3+ or immunohistochemistry 2+/fluorescence in situ hybridization-positive or immunohistochemistry 2+/silver in situ hybridization-positive) metastatic adenocarcinoma of the stomach or gastro-esophageal junction. Cisplatin 67-76 erb-b2 receptor tyrosine kinase 2 Homo sapiens 163-197 22222640-1 2012 Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the European Medicines Agency for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive (immunohistochemistry 3+ or immunohistochemistry 2+/fluorescence in situ hybridization-positive or immunohistochemistry 2+/silver in situ hybridization-positive) metastatic adenocarcinoma of the stomach or gastro-esophageal junction. Cisplatin 67-76 erb-b2 receptor tyrosine kinase 2 Homo sapiens 199-203 22313686-2 2012 In the presence of gefitinib, cisplatin-induced growth inhibition and apoptosis were significantly enhanced in Caov-3 and RMG-1 cells, which express EGFR, and in A2780, which lacks EGFR but expresses HER-2. Cisplatin 30-39 erb-b2 receptor tyrosine kinase 2 Homo sapiens 200-205 21712253-6 2011 Furthermore, we found that HER2 overexpression led to an increased resistance of MCF7 cells to multiple antitumor drugs such as paclitaxel (Taxol), cisplatin (DDP), etoposide (VP-16), adriamycin (ADM), mitoxantrone (MX), and 5-fluorouracil (5-FU). Cisplatin 159-162 erb-b2 receptor tyrosine kinase 2 Homo sapiens 27-31 23422737-10 2012 HM781-36B combined with 5-fluorouracil, cisplatin, paclitaxel, or gemcitabine showed a synergistic inhibitory effect on the HER2-amplified and on some of the HER2-nonamplified breast cancer cells. Cisplatin 40-49 erb-b2 receptor tyrosine kinase 2 Homo sapiens 124-128 23422737-10 2012 HM781-36B combined with 5-fluorouracil, cisplatin, paclitaxel, or gemcitabine showed a synergistic inhibitory effect on the HER2-amplified and on some of the HER2-nonamplified breast cancer cells. Cisplatin 40-49 erb-b2 receptor tyrosine kinase 2 Homo sapiens 158-162 23007148-1 2012 BACKGROUND: Trastuzumab in combination with doublet chemotherapy (cisplatin and fluoropyrimidine) is a standard treatment for patients with HER2-positive advanced gastric cancer. Cisplatin 66-75 erb-b2 receptor tyrosine kinase 2 Homo sapiens 140-144 21993011-0 2011 A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer. Cisplatin 42-51 erb-b2 receptor tyrosine kinase 2 Homo sapiens 80-85 21712253-6 2011 Furthermore, we found that HER2 overexpression led to an increased resistance of MCF7 cells to multiple antitumor drugs such as paclitaxel (Taxol), cisplatin (DDP), etoposide (VP-16), adriamycin (ADM), mitoxantrone (MX), and 5-fluorouracil (5-FU). Cisplatin 148-157 erb-b2 receptor tyrosine kinase 2 Homo sapiens 27-31 20417484-4 2010 High HER-2/neu expressors were more sensitive to platinum compounds, manifesting a 5.22-fold decrease in carboplatin-IC(50) (P = .005) and a 5.37-fold decrease in cisplatin-IC(50) (P = .02). Cisplatin 163-172 erb-b2 receptor tyrosine kinase 2 Homo sapiens 5-14 21421462-0 2011 Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Cisplatin 34-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 83-87 21421462-13 2011 CONCLUSIONS: Trastuzumab in combination with cisplatin is an active regimen and has a favourable toxicity profile in advanced HER2-positive gastric or gastroesophageal cancers. Cisplatin 45-54 erb-b2 receptor tyrosine kinase 2 Homo sapiens 126-130 21874111-11 2011 The choice between ecf and eox should be based on patient preference.Trastuzumab in combination with cisplatin and a fluoropyrimidine (5fu or oral capecitabine) is recommended for advanced gastric cancer positive for the human epidermal growth factor receptor 2 (her2/neu). Cisplatin 101-110 erb-b2 receptor tyrosine kinase 2 Homo sapiens 227-261 21651462-8 2011 Trastuzumab in combination with cisplatin/5-fluoropyrimidine-based chemotherapy is the new standard of care for patients with HER2-positive advanced gastric cancer. Cisplatin 32-41 erb-b2 receptor tyrosine kinase 2 Homo sapiens 126-130 21129604-7 2010 Based on these results trastuzumab combined with a cisplatin and fluoropyrimidine regimen appear the new reference treatment for HER-2 positive metastatic gastric cancer. Cisplatin 51-60 erb-b2 receptor tyrosine kinase 2 Homo sapiens 129-134 20238327-19 2010 Two and three-drug regimens including 5-FU, cisplatin, with or without an anthracycline, as well as irinotecan or docetaxel-containing regimens are reasonable treatment options for HER-2 negative patients. Cisplatin 44-53 erb-b2 receptor tyrosine kinase 2 Homo sapiens 181-186 20057287-0 2010 Cisplatin-based radiochemotherapy improves the negative prognosis of c-erbB-2 overexpressing advanced cervical cancer. Cisplatin 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 69-77 19800108-8 2009 Mass spectrometry and flow cytometry confirmed the over-expression of CD49f, CD70 and Her-2/neu in other cisplatin resistant ovarian cancer cell lines. Cisplatin 105-114 erb-b2 receptor tyrosine kinase 2 Homo sapiens 86-95 19292937-0 2009 The role of HER2 in metastatic breast cancer treated with a combination of taxanes and cisplatin. Cisplatin 87-96 erb-b2 receptor tyrosine kinase 2 Homo sapiens 12-16 19513620-3 2009 And the effects of Herceptin, AG825 and Cisplatin on the expression of nuclear ERBB2 were investigated. Cisplatin 40-49 erb-b2 receptor tyrosine kinase 2 Homo sapiens 79-84 19513620-7 2009 Cisplatin also induced the nuclear ERBB2 expression in breast cancer cells with high ERBB2 expression. Cisplatin 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 35-40 19513620-7 2009 Cisplatin also induced the nuclear ERBB2 expression in breast cancer cells with high ERBB2 expression. Cisplatin 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 85-90 19887555-12 2009 Transfection of HER2 into MDA-MB-468 cells inhibited the repair of cisplatin-induced ICL, whereas transfection of a HER2 construct lacking the nuclear localization sequence did not affect DNA repair. Cisplatin 67-76 erb-b2 receptor tyrosine kinase 2 Homo sapiens 16-20 19575783-0 2009 The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients. Cisplatin 33-42 erb-b2 receptor tyrosine kinase 2 Homo sapiens 14-18 19575783-15 2009 CONCLUSION: Non-small cell lung cancer patients with high expression of HER2 exhibited resistance to cisplatin-based chemotherapies that are the standard treatment for this disease. Cisplatin 101-110 erb-b2 receptor tyrosine kinase 2 Homo sapiens 72-76 19575783-16 2009 Our results indicate that HER2 status may be a predictive and prognostic factor for cisplatin- based therapy response and disease survival. Cisplatin 84-93 erb-b2 receptor tyrosine kinase 2 Homo sapiens 26-30 19292937-2 2009 The purpose of this study was to retrospectively assess whether HER2 is associated with clinical sensitivity or with prognostic significance in breast cancer patient groups who had received chemotherapy with taxanes and cisplatin. Cisplatin 220-229 erb-b2 receptor tyrosine kinase 2 Homo sapiens 64-68 19292937-12 2009 CONCLUSIONS: Our results indicated that HER2 status is independent of a response to a taxanes/cisplatin combination and is also not a prognostic factor for survival. Cisplatin 94-103 erb-b2 receptor tyrosine kinase 2 Homo sapiens 40-44